Ana Kostic, PhD is an Associate Professor of Psychiatry at the Icahn School of Medicine at Mount Sinai, and the Director of Drug Discovery and Development at the Seaver Autism Center for Research and Treatment. Dr. Kostic is a clinical scientist with expertise in drug development, biomarkers, patient selection and stratification. She received her PhD and postdoctoral training in molecular and cell biology at Columbia University.
Dr. Kostic spent eleven years in the biotech/pharmaceutical industry prior to joining Mount Sinai. She worked in various roles across preclinical, clinical and precision medicine at Regeneron Pharmaceuticals and as Senior Director of Translational Medicine at Kiniksa Pharmaceuticals.
The main focus of Dr. Kostic’s research at Mount Sinai is to identify potential drug candidates for treatment of autism, design experimental strategies for testing in neuronal cell systems and animal models, as well as to discover and validate molecular biomarkers in autism. Specifically, her group is interested in ADNP, DDX3X, FOXP1, and Phelan-McDermid syndromes, common single-gene causes of autism.
Dr. Kostic co-leads collaborations between the Seaver Autism Center and several pharmaceutical companies as well as with other academic groups. The main goal of these collaborations is to build a drug discovery pipeline and enable testing of existing drug candidates. Current partners include Scripps Florida, Rumi Scientific, Oryzon and NeuCyte.
Education
BSc, University of Belgrade
MA, Columbia University
MPhil, Columbia University
PhD, Columbia University
Postdoctoral Fellow, Columbia University
-
2010
Top '40-under-40' of Westchester County -
2001
Scholarship and Travel Award -
2000
Valedictorian -
1999
IASTE Research Internship Award
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Dr. Kostic did not report having any of the following types of financial relationships with industry during 2020 and/or 2021: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.